Melinta Therapeutics (NASDAQ:MLNT) will be announcing its earnings results after the market closes on Wednesday, March 13th. Analysts expect the company to announce earnings of ($5.03) per share for the quarter.
Shares of NASDAQ:MLNT opened at $4.77 on Tuesday. The company has a quick ratio of 1.04, a current ratio of 1.34 and a debt-to-equity ratio of 0.46. Melinta Therapeutics has a one year low of $3.20 and a one year high of $67.75. The firm has a market capitalization of $50.42 million, a price-to-earnings ratio of -0.04 and a beta of 2.13.
A hedge fund recently raised its stake in Melinta Therapeutics stock. Geode Capital Management LLC lifted its stake in shares of Melinta Therapeutics Inc (NASDAQ:MLNT) by 3.3% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 418,753 shares of the biotechnology company’s stock after acquiring an additional 13,337 shares during the period. Geode Capital Management LLC owned approximately 3.74% of Melinta Therapeutics worth $331,000 as of its most recent SEC filing. Institutional investors and hedge funds own 67.15% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Melinta Therapeutics (MLNT) Scheduled to Post Quarterly Earnings on Wednesday” was originally published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this piece on another site, it was illegally stolen and reposted in violation of international copyright and trademark law. The legal version of this piece can be viewed at https://sportsperspectives.com/2019/03/12/melinta-therapeutics-mlnt-scheduled-to-post-quarterly-earnings-on-wednesday.html.
About Melinta Therapeutics
Melinta Therapeutics, Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes various anti-infectives for the treatment of bacterial infectious diseases in North America. It offers Baxdela, an antibiotic for the treatment of acute bacterial skin and skin structure infections (ABSSSI); Vabomere, a carbapenem used in treatment of gram-negative infections; Orbactiv, an antibiotic of the lipoglycopeptide class for the treatment of adult patients with ABSSSIs; and Minocin, a IV antibiotic of the tetracycline class with activity against gram-positive and gram-negative pathogens, as well as Solithromycin, a macrolide antibiotic for the treatment of CABP.
Further Reading: Momentum Investing
Receive News & Ratings for Melinta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Melinta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.